Question: Who is responsible for the financial loss when medications expire while awaiting HMO or insurance reimbursement? Can the cost be recovered from the HMO, or does it fall entirely on the healthcare provider?
Case scenario
A hospital pharmacy in Abuja procures high-cost medications for patients covered under an HMO plan. Due to administrative delays in HMO approvals and reimbursement, some drugs remain in storage and eventually expire. The pharmacy seeks reimbursement for the expired drugs from the HMO, but the HMO declines, arguing that reimbursement is only for dispensed and utilized medications.
The hospital considers passing the loss to patients but fears potential legal action. Who legally bears the financial loss in such circumstances?
Legal perspective
Under Nigerian law, the interaction between healthcare providers and HMOs is largely contractual. The question of financial responsibility for expired medications is determined by the terms of the HMO-provider agreement rather than clinical obligations. Key considerations include:
- Contractual terms on risk allocation – Does the agreement specify who bears the cost of expired stock or unutilised drugs?
- Timing and authorisation – Was the delay in reimbursement caused by the HMO, and are there clauses addressing delays?
- Ownership of drugs – Legally, the party that owns the drugs until dispensation may bear the risk of loss.
- Patient status – Patients are usually not parties to the contract; therefore, liability typically cannot be shifted to them without explicit consent.
- Regulatory framework – NHIA or state insurance guidelines may have provisions on drug wastage or reimbursement procedures.
Courts generally treat expired drugs awaiting reimbursement as a commercial risk unless the contract explicitly transfers this risk to the HMO.
Determining liability
When assessing liability, courts may consider:
Contract clauses: Whether the HMO agreement defines responsibility for stock losses or expired drugs.
Cause of delay: Whether the delay in reimbursement was due to administrative fault by the HMO or operational inefficiency of the provider.
Good faith communication: Whether the provider promptly informed the HMO of impending stock expiration and sought resolution.
Industry standards: Standard practices regarding inventory management and risk sharing between providers and insurers.
Liability is more likely to fall on the HMO where the contract stipulates reimbursement obligations regardless of stock expiry, or where the HMO caused unreasonable delays. Otherwise, the financial loss may be deemed a business risk of the provider.
Defences available to hospitals and pharmacies
- Contractual risk allocation: The provider assumes the risk of expired stock unless otherwise agreed.
- Prompt notification: Documentation showing the provider notified the HMO of pending expiry and sought timely approval.
- Non-emergency nature: The drugs were not required for immediate life-saving treatment.
- Regulatory compliance: The provider acted in accordance with NHIA and professional guidelines.
5.Commercial impracticability: The provider may claim economic impossibility of operating at a loss if HMO tariffs or reimbursement terms do not cover cost.
Practical advice
Ensure HMO agreements clearly define risk allocation for stock expiry and delayed reimbursements.
Implement inventory controls and review stock regularly to prevent unnecessary losses.
Maintain clear, written communication with HMOs regarding pending approvals and reimbursements.
Document all cases of expiry and steps taken to mitigate loss.
Consider insurance or risk-sharing arrangements for high-cost medications.
Closing insight
While healthcare providers are driven by patient care, Nigerian law recognises that commercial arrangements with HMOs carry financial risk. Clear contractual terms, proactive communication, and prudent stock management remain the most effective tools to minimise loss and avoid disputes.
